Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2291112
下载链接
链接失效反馈官方服务：
资源简介：
To evaluate the safety and tolerability of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers. Patients will be followed long-term for Overall Survival (OS) and safety. The study will enroll approximately 90 patients and maximum study treatment duration is approximately 2.13 years.
创建时间：
2019-06-15
